US Stocks Movement: Biohaven Surges on November 19 as BHV-1530 Clinical Data, FGFR3 ADC, and Pivotal Trials Drive Gains
Bitget异动解读2026/11/19 15:21Biohaven Soars on November 19: Analysis
Keywords: BHV-1530 clinical data, FGFR3 ADC, pivotal trial
1. On November 19, at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics held in Barcelona, Spain, Biohaven presented ongoing Phase 1 clinical data for BHV-1530 in an oral plenary session. As of the data cut-off date, among 10 evaluable patients with FGFR3 activating genetic alterations treated at doses ≥3.3 mg/kg, 6 showed objective responses and 9 experienced tumor shrinkage. No dose-limiting toxicities, treatment-related serious adverse events, or treatment-related deaths were reported among the 30 treated patients.
2. The company plans to initiate a pivotal trial of BHV-1530 for FGFR3-mutated tumors in the first half of 2027, having previously held a Type C meeting with the U.S. Food and Drug Administration to support potential accelerated approval.
3. Biohaven is a biopharmaceutical company focused on therapies in the fields of immunology, obesity, neuroscience, and oncology. BHV-1530 is an antibody-drug conjugate targeting FGFR3 and carries a topoisomerase I payload.
(Disclaimer: This content is generated by AI technology summarizing publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US President Donald Trump’s Company May Face $883.5 Million in Debt! Will Bitcoins Be Sold?

Spot platinum exceeds $1,370 per ounce
US Stocks Movement: PACS plunged on November 19 due to overvaluation and pressure on discounted cash flow